CN104520300B - 作为激酶抑制剂的咪唑并[1,2-b]哒嗪衍生物 - Google Patents

作为激酶抑制剂的咪唑并[1,2-b]哒嗪衍生物 Download PDF

Info

Publication number
CN104520300B
CN104520300B CN201380041498.XA CN201380041498A CN104520300B CN 104520300 B CN104520300 B CN 104520300B CN 201380041498 A CN201380041498 A CN 201380041498A CN 104520300 B CN104520300 B CN 104520300B
Authority
CN
China
Prior art keywords
compound
amino
imidazo
phenyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380041498.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104520300A (zh
Inventor
武田泰幸
吉川谦次
神子岛佳子
山本裕子
田中亮
田中亮一
富永裕
富永裕一
木我真基
浜田义人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of CN104520300A publication Critical patent/CN104520300A/zh
Application granted granted Critical
Publication of CN104520300B publication Critical patent/CN104520300B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201380041498.XA 2012-06-04 2013-06-03 作为激酶抑制剂的咪唑并[1,2-b]哒嗪衍生物 Active CN104520300B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-127079 2012-06-04
JP2012127079 2012-06-04
PCT/JP2013/065328 WO2013183578A1 (ja) 2012-06-04 2013-06-03 キナーゼ阻害剤としてのイミダゾ[1,2-b]ピリダジン誘導体

Publications (2)

Publication Number Publication Date
CN104520300A CN104520300A (zh) 2015-04-15
CN104520300B true CN104520300B (zh) 2016-12-21

Family

ID=49711970

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380041498.XA Active CN104520300B (zh) 2012-06-04 2013-06-03 作为激酶抑制剂的咪唑并[1,2-b]哒嗪衍生物

Country Status (32)

Country Link
US (2) US9187489B2 (enExample)
EP (1) EP2857404B1 (enExample)
JP (1) JP5814467B2 (enExample)
KR (1) KR101781255B1 (enExample)
CN (1) CN104520300B (enExample)
AU (1) AU2013272701B2 (enExample)
BR (1) BR112014029851B1 (enExample)
CA (1) CA2874819C (enExample)
CO (1) CO7160119A2 (enExample)
CY (1) CY1119607T1 (enExample)
DK (1) DK2857404T3 (enExample)
ES (1) ES2648228T3 (enExample)
HR (1) HRP20171724T1 (enExample)
HU (1) HUE037221T2 (enExample)
IL (1) IL236075A (enExample)
IN (1) IN2014MN02497A (enExample)
LT (1) LT2857404T (enExample)
MX (1) MX357021B (enExample)
MY (1) MY170326A (enExample)
NO (1) NO2857404T3 (enExample)
NZ (1) NZ702574A (enExample)
PH (1) PH12014502721B1 (enExample)
PL (1) PL2857404T3 (enExample)
PT (1) PT2857404T (enExample)
RS (1) RS56625B1 (enExample)
RU (1) RU2635917C2 (enExample)
SG (1) SG11201408052WA (enExample)
SI (1) SI2857404T1 (enExample)
SM (1) SMT201700539T1 (enExample)
TW (1) TWI585088B (enExample)
WO (1) WO2013183578A1 (enExample)
ZA (1) ZA201408843B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2350075T3 (da) 2008-09-22 2014-05-26 Array Biopharma Inc Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer
PT3106463T (pt) 2008-10-22 2018-05-18 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
RU2735545C2 (ru) 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Макроциклические соединения в качестве ингибиторов киназы trk
AU2013268400B2 (en) 2012-05-30 2017-07-13 Nippon Shinyaku Co., Ltd. Aromatic heterocyclic derivative and pharmaceutical
WO2015144801A1 (en) * 2014-03-27 2015-10-01 Janssen Pharmaceutica Nv SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS
CN106164076B (zh) 2014-03-27 2019-03-26 詹森药业有限公司 作为ros1抑制剂的化合物
EP3906921A1 (en) * 2014-04-25 2021-11-10 Exelixis, Inc. Method of treating lung adenocarcinoma
EP3218380B1 (en) 2014-11-16 2021-03-17 Array Biopharma, Inc. Preparation of a crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
PE20180329A1 (es) 2015-06-01 2018-02-13 Loxo Oncology Inc Metodos para diagnosticar y tratar el cancer
BR112017027339A2 (pt) 2015-06-18 2018-09-04 Cephalon, Inc. derivados de piperidina 1,4-substituída
US10919875B2 (en) 2015-06-18 2021-02-16 89Bio Ltd Substituted 4-benzyl and 4-benzoyl piperidine derivatives
PT3322706T (pt) 2015-07-16 2021-03-08 Array Biopharma Inc Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret
TN2019000271A1 (en) 2015-10-26 2021-01-07 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
CN106854174A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4位取代哌啶衍生物的制备方法
IL304018A (en) 2016-04-04 2023-08-01 Loxo Oncology Inc Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
TN2019000332A1 (en) 2016-04-04 2021-05-07 Loxo Oncology Inc Methods of treating pediatric cancers
ES2952056T3 (es) 2016-05-18 2023-10-26 Loxo Oncology Inc Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
CN107400082A (zh) * 2016-05-19 2017-11-28 湖南华腾制药有限公司 一种取代哌啶衍生物的制备方法
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物
CA3055504A1 (en) * 2017-03-14 2018-09-20 Daiichi Sankyo Company, Limited Method for producing 3,6-disubstituted imidazo[1,2-b]pyridazine derivative
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109748902B (zh) * 2017-11-02 2020-11-06 杭州科巢生物科技有限公司 一种盐酸安罗替尼的制备方法
KR102078775B1 (ko) 2017-11-29 2020-02-19 서울대학교산학협력단 항-ros1 항체 및 그의 용도
CN108129288B (zh) * 2017-12-27 2021-01-22 上海毕得医药科技股份有限公司 一种反式-3-羟基环丁基甲酸的合成方法
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての置換ピラゾリル[4,3-c]ピリジン化合物
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
US20210023086A1 (en) 2018-03-29 2021-01-28 Loxo Oncology, Inc. Treatment of trk-associated cancers
MX2021000795A (es) 2018-07-24 2021-04-12 Taiho Pharmaceutical Co Ltd Compuestos heterociclicos para inhibir la actividad de shp2.
JP7286755B2 (ja) 2018-07-31 2023-06-05 ロクソ オンコロジー, インコーポレイテッド (s)-5-アミノ-3-(4-((5-フルオロ-2-メトキシベンズアミド)メチル)フェニル)-1-(1,1,1-トリフルオロプロパン-2-イル)-1h-ピラゾール-4-カルボキサミドの噴霧乾燥分散体および製剤
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド FGFRチロシンキナーゼの阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3,5-二甲氧基苯基)氨基)喹喔啉衍生物
CN113543852A (zh) * 2019-03-06 2021-10-22 第一三共株式会社 吡咯并吡唑衍生物
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
WO2020224626A1 (zh) * 2019-05-08 2020-11-12 浙江同源康医药股份有限公司 用作激酶抑制剂的化合物及其应用
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
CN114957259A (zh) * 2021-02-25 2022-08-30 南京明德新药研发有限公司 氰基取代的芳香双环类化合物及其应用
WO2023272701A1 (en) * 2021-07-01 2023-01-05 Anheart Therapeutics (Hangzhou) Co., Ltd. Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof
JP2025515952A (ja) * 2022-05-18 2025-05-20 アンハート セラピューティクス(ハンチョウ)コーポレーション,リミテッド 3,6-二置換-イミダゾ[1,2-b]ピリダジン化合物の製造方法
CN114989176B (zh) * 2022-07-08 2024-08-27 深圳市新樾生物科技有限公司 咪唑并哒嗪类衍生物及其应用
CN115197115B (zh) * 2022-08-25 2024-11-08 成都金博汇康医药科技有限公司 一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用
US20260028352A1 (en) 2022-09-07 2026-01-29 Suzhou Langrui Biopharmaceutical Co., Ltd. Macrocyclic imidazo [1,2-b] pyridazine derivative, preparation method therefor, and use thereof
CN117659020A (zh) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008072682A1 (ja) * 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ[1,2-b]ピリダジン誘導体
US20080167314A1 (en) * 2004-12-28 2008-07-10 Osamu Uchikawa Condensed Imidazole Compound And Use Thereof
CN101522682A (zh) * 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
JP2009227599A (ja) * 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
WO2011049332A2 (en) * 2009-10-22 2011-04-28 Korea Institute Of Science And Technology 2,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors
CN102056927A (zh) * 2008-05-13 2011-05-11 Irm责任有限公司 作为激酶抑制剂的稠合含氮杂环及其组合物
CN102224153A (zh) * 2008-09-22 2011-10-19 阵列生物制药公司 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US7071217B2 (en) 2000-09-01 2006-07-04 Smithkline Beecham Corporation Substituted oxindole derivatives as tyrosine kinase inhibitors
AU8664701A (en) 2000-09-01 2002-03-22 Glaxo Group Ltd Oxindole derivatives
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005103010A2 (en) 2004-04-21 2005-11-03 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
NZ561145A (en) 2005-02-04 2011-02-25 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EP1853602B1 (en) 2005-02-16 2010-07-14 AstraZeneca AB Chemical compounds
SI1853588T1 (sl) 2005-02-16 2008-10-31 Astrazeneca Ab Kemične spojine
EP1910369A1 (en) 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
US7776878B2 (en) * 2005-08-01 2010-08-17 Hoffmann-La Roche Inc. Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102006029447A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
WO2008058126A2 (en) * 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
JPWO2012005299A1 (ja) 2010-07-07 2013-09-05 日本新薬株式会社 Rosチロシンキナーゼ阻害剤
WO2012125667A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080167314A1 (en) * 2004-12-28 2008-07-10 Osamu Uchikawa Condensed Imidazole Compound And Use Thereof
CN101522682A (zh) * 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
WO2008072682A1 (ja) * 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ[1,2-b]ピリダジン誘導体
JP2009227599A (ja) * 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
CN102056927A (zh) * 2008-05-13 2011-05-11 Irm责任有限公司 作为激酶抑制剂的稠合含氮杂环及其组合物
CN102224153A (zh) * 2008-09-22 2011-10-19 阵列生物制药公司 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物
WO2011049332A2 (en) * 2009-10-22 2011-04-28 Korea Institute Of Science And Technology 2,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors

Also Published As

Publication number Publication date
KR20150014942A (ko) 2015-02-09
US20160046639A1 (en) 2016-02-18
KR101781255B1 (ko) 2017-09-22
TWI585088B (zh) 2017-06-01
RU2635917C2 (ru) 2017-11-17
MY170326A (en) 2019-07-17
NZ702574A (en) 2016-07-29
JP5814467B2 (ja) 2015-11-17
HK1207374A1 (en) 2016-01-29
US9187489B2 (en) 2015-11-17
PH12014502721A1 (en) 2015-02-02
WO2013183578A1 (ja) 2013-12-12
AU2013272701A2 (en) 2015-01-22
BR112014029851B1 (pt) 2023-01-03
AU2013272701B2 (en) 2017-12-21
LT2857404T (lt) 2017-11-10
SI2857404T1 (sl) 2017-11-30
PT2857404T (pt) 2017-11-23
MX357021B (es) 2018-06-25
HRP20171724T1 (hr) 2018-01-12
IL236075A (en) 2017-10-31
PH12014502721B1 (en) 2015-02-02
NO2857404T3 (enExample) 2018-01-20
AU2013272701A1 (en) 2015-01-15
EP2857404A4 (en) 2016-01-20
RU2014153627A (ru) 2016-08-10
DK2857404T3 (en) 2017-12-04
CA2874819C (en) 2017-06-20
RS56625B1 (sr) 2018-03-30
PL2857404T3 (pl) 2018-04-30
ZA201408843B (en) 2016-01-27
EP2857404B1 (en) 2017-08-23
US20150051190A1 (en) 2015-02-19
JPWO2013183578A1 (ja) 2016-01-28
BR112014029851A2 (pt) 2017-06-27
TW201400486A (zh) 2014-01-01
IN2014MN02497A (enExample) 2015-07-17
CY1119607T1 (el) 2018-04-04
ES2648228T3 (es) 2017-12-29
CA2874819A1 (en) 2013-12-12
SMT201700539T1 (it) 2018-01-11
IL236075A0 (en) 2015-02-01
CO7160119A2 (es) 2015-01-15
US9751887B2 (en) 2017-09-05
HUE037221T2 (hu) 2018-08-28
CN104520300A (zh) 2015-04-15
EP2857404A1 (en) 2015-04-08
SG11201408052WA (en) 2015-01-29
MX2014014803A (es) 2015-02-12

Similar Documents

Publication Publication Date Title
CN104520300B (zh) 作为激酶抑制剂的咪唑并[1,2-b]哒嗪衍生物
JP7033764B2 (ja) Cdk阻害剤としての置換型ヘテロシクリル誘導体
JP7254094B2 (ja) Prmt5阻害剤としての置換イミダゾリジン-2-オン誘導体
JP5639261B2 (ja) ピラゾリルキノキサリンキナーゼ阻害剤
MX2007009842A (es) Compuestos quimicos.
CN115315422B (zh) 酰胺类化合物及其用途
EP3694331A1 (en) Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
US12552785B2 (en) Pyrazolo[1,5-α]pyridine derivative, preparation method therefor, and composition and use thereof
HK1207374B (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
HK40109089A (zh) 酰胺类化合物及其用途
HK40105207A (zh) 酰胺类化合物及其用途
HK40104416A (zh) 酰胺类化合物及其用途
HK40082804A (en) Amide compounds and uses thereof
HK40082804B (zh) 酰胺类化合物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant